Permission was obtained from the Ministry of Health of the Russian Federation to conduct three Phase III clinical trials to assess the efficacy and safety of a new oral medicine for patients with moderate or severe Crohn's disease, sponsored by the pharmaceutical company Selgene, Switzerland.
Congratulations to the AMAM Study team on the successful completion of the audit of the sponsor of the pharmaceutical company Eli Lilly!
The Site's participation in three clinical trials of drugs for the treatment of ulcerative colitis was approved by the sponsor of the study - the pharmaceutical company Pfizer.
A new visit of the site's initiation: sublingual immunotherapy of tree pollen allergy, sponsored by the pharmaceutical company ALK-Abello, Denmark. We invite patients from 5 to 17 years old!
